Laennec (human placenta hydrolyzate) / GC Biopharma - LARVOL DELTA

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop (clinicaltrials.gov) - P3 | N=226 | Not yet recruiting | Sponsor: Green Cross Wellbeing

New P3 trial • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease

Ministry of Food and Drug Safety approves clinical plan for COVID-19 treatment of placenta injection ’Rineek’ [Google translation] (Hankyung) - "The Ministry of Food and Drug Safety announced on the 26th that it has approved a phase 2 clinical trial plan to confirm the effectiveness of the treatment of the novel coronavirus infection (Corona 19) of Rineek (self-hydrolyzate), commonly referred to as a placental injection....This clinical trial was designed to evaluate the efficacy and safety of Rineek in corona19 patients. Rineek is currently a drug that is administered subcutaneously or intramuscularly, but in this clinical trial, it was decided to change to intravenous administration."

New P2 trial • Infectious Disease • Novel Coronavirus Disease